LEADER Trial Cost-Effectiveness: Is Liraglutide Worth the Price for Cardiovascular Protection?

By
Published Updated Last reviewed
Prescription access and medication affordability image for LEADER Trial Cost-Effectiveness: Is Liraglutide Worth the Price for Cardiovascular Protection?

At a glance

| Trial detail | Value | |---|---| | Trial name | LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) | | N | 9,340 | | Intervention | Liraglutide 1.8 mg daily (subcutaneous) | | Comparator | Placebo (both arms received standard of care) | | Median follow-up | 3.8 years | | Primary endpoint | First occurrence of 3-point MACE (CV death, nonfatal MI, nonfatal stroke) | | Key result | HR 0.87 to 95% CI 0.78, 0.97; 13% relative risk reduction (Marso et al., NEJM 2016) |

Why a Cost Question Followed the Clinical One

When LEADER reported a statistically significant 13% reduction in three-point MACE, liraglutide became the first GLP-1 receptor agonist to demonstrate cardiovascular benefit in a dedicated outcomes trial. The clinical signal was clear. The economic signal was not. Liraglutide carried a wholesale acquisition cost (WAC) above $1,000 per month in the United States, roughly 30 to 50 times the price of metformin or generic sulfonylureas. Payers, formulary committees, and patients all asked the same question: does a 13% relative risk reduction in MACE justify that premium?

Multiple groups attempted to answer this through cost-effectiveness analysis (CEA), each using slightly different modeling assumptions. The variation in their conclusions reveals as much about health-economic methodology as it does about liraglutide itself.

The Core Modeling Approaches

Novo Nordisk-Sponsored Analysis (CORE Diabetes Model)

The manufacturer funded a CEA using the IMS CORE Diabetes Model, a validated microsimulation platform that projects long-term diabetes complications from short-term trial inputs. This analysis took LEADER's 3.8-year clinical data, including HbA1c trajectories, weight changes, hypoglycemia rates, and cardiovascular event rates, and extrapolated them over a patient lifetime horizon.

Key inputs and outputs:

| Parameter | Value used | |---|---| | Time horizon | Patient lifetime (simulated ~40 years from enrollment age) | | Discount rate | 3% annually for costs and outcomes | | Perspective | US healthcare payer | | WAC for liraglutide | ~$1,100/month (2017 USD) | | Incremental cost | $30,000, $42,000 over lifetime | | Incremental QALYs | 0.26, 0.42 | | ICER | $102,000, $161,000 per QALY |

The range in the incremental cost-effectiveness ratio (ICER) depended on assumptions about long-term treatment duration. If patients stayed on liraglutide for life, costs accumulated but so did projected cardiovascular benefit. If treatment was assumed to stop at five years with residual benefit decaying, the ICER improved.

ICER (Institute for Clinical and Economic Review) Assessment

ICER conducted an independent evaluation of GLP-1 receptor agonists for type 2 diabetes and published results that were less favorable to liraglutide. Their base-case ICER for liraglutide versus standard care in the LEADER-like population landed near $150,000 to $200,000 per QALY. ICER flagged that at list price, liraglutide did not meet the commonly cited $150,000/QALY threshold used in US value assessments.

ICER recommended a price reduction of 40 to 60% to meet a $100,000, $150,000/QALY benchmark. This recommendation had practical consequences: several pharmacy benefit managers cited the ICER report when negotiating rebate structures.

UK and Scandinavian Perspective

European analyses using LEADER data reached different conclusions because of different drug prices. In the UK, where the NHS negotiates prices well below US list levels, several models placed liraglutide at £20,000, £30,000 per QALY, comfortably within the NICE willingness-to-pay threshold of £20,000, £30,000. Swedish analyses similarly found cost-effectiveness at local pricing. The drug's economic profile was not inherently unfavorable. It was unfavorable at US list prices specifically.

List Price vs. Net Price: The Number That Actually Matters

A persistent problem with US-based CEAs of branded diabetes drugs is the gap between WAC and the net price after rebates, which manufacturers negotiate confidentially with PBMs and insurers. For liraglutide (Victoza), estimates of the net-to-gross ratio have ranged from 0.45 to 0.65, meaning payers may have been paying $500, $715 per month rather than $1,100.

When CEA models substituted estimated net prices for WAC, ICERs dropped substantially. At a net price of $550/month, the manufacturer-sponsored model produced ICERs near $60,000, $80,000 per QALY, well within standard US thresholds. This math reveals a structural frustration in US pharmacoeconomics: the published CEA uses a price that few payers actually pay, but the real price is hidden behind confidentiality agreements.

The practical effect was a policy stalemate. Public-facing analyses said liraglutide was borderline or cost-ineffective. Behind-the-scenes negotiations may have achieved prices that were genuinely cost-effective. Patients saw the list price on their benefit summaries and often faced significant copays calibrated to that number, not the net.

Who Gets the Most Value? Subgroup Economics

Not all patients in LEADER benefited equally. The cardiovascular risk reduction was driven most strongly by patients with established cardiovascular disease at baseline, not those with risk factors alone. Post-hoc analyses showed that the HR for MACE in the established-CVD subgroup was lower (more favorable) than in the risk-factor-only subgroup.

This clinical heterogeneity has direct economic implications:

| Subgroup | Estimated ICER (US, WAC) | Estimated ICER (US, net price) | |---|---|---| | Established CVD (prior MI, stroke, or PAD) | $80,000, $110,000/QALY | $45,000, $65,000/QALY | | Risk factors only (no prior event) | $200,000, $350,000/QALY | $120,000, $200,000/QALY |

For patients who have already had a cardiovascular event, the absolute risk reduction is larger because the baseline event rate is higher. Liraglutide's value proposition concentrates here. For patients with risk factors but no prior event, the number needed to treat (NNT) is higher, the absolute benefit smaller, and the cost per averted event rises sharply.

This distinction matters for formulary design. Some insurers adopted tiered prior-authorization criteria that granted coverage preferentially to patients with established atherosclerotic cardiovascular disease, effectively implementing value-based coverage from the subgroup data.

Comparison with Later GLP-1 Agents

LEADER was published in 2016. The SUSTAIN-6 trial for semaglutide and later the SELECT trial for higher-dose semaglutide shifted economic calculations because semaglutide showed a numerically larger MACE reduction. Once-weekly dosing (semaglutide) versus once-daily dosing (liraglutide) also introduced convenience and adherence differentials that CEA models attempted to capture.

By 2024, liraglutide had lost significant GLP-1 market share to semaglutide products. The economic question shifted from "is liraglutide cost-effective versus placebo?" to "is liraglutide cost-effective versus semaglutide?" Most head-to-head economic models favored semaglutide on both efficacy and convenience grounds, particularly after Ozempic gained broad formulary placement.

Limitations the Authors and Modelers Acknowledged

Economic models built on LEADER data carry several acknowledged weaknesses:

  1. Extrapolation beyond trial duration. LEADER ran 3.8 years. Lifetime models project 30+ years of hypothetical benefit and cost. Small changes in assumed benefit persistence produce large ICER swings.

  2. HbA1c as a surrogate driver. Many diabetes simulation models use HbA1c as a primary input for complication risk. LEADER's cardiovascular benefit appeared partially independent of glycemic control, which the models captured imperfectly.

  3. Competing risks in an aging population. LEADER enrolled patients with a mean age of 64. Over a lifetime horizon, competing mortality from non-cardiovascular causes dilutes the projected QALY gains from a CV-specific intervention.

  4. Adherence assumptions. Trial adherence exceeds real-world adherence. Patients in LEADER received free drug and regular follow-up. In clinical practice, out-of-pocket costs and injection burden reduce persistence, which worsens real-world cost-effectiveness.

  5. Price instability. WAC for Victoza changed multiple times between 2016 and 2024, and rebate structures shifted even faster. Any published ICER is a snapshot tied to a specific price assumption that may be obsolete within months.

What This Means for an Individual Patient

For someone sitting across from a clinician, the cost-effectiveness literature offers a practical framework rather than a binary answer.

If a patient has established cardiovascular disease, a history of MI or stroke, and type 2 diabetes, the economic case for a GLP-1 receptor agonist is strong. The MACE reduction is concentrated in this group. The cost per prevented event is lowest here. Insurance is most likely to approve coverage with a prior-event history documented.

If a patient has type 2 diabetes with risk factors but no prior cardiovascular event, the clinical benefit is less certain and the cost per QALY climbs. The decision depends on how much the patient pays out of pocket, whether alternatives (SGLT2 inhibitors, high-dose statins) are already optimized, and personal risk tolerance.

In either case, the actual out-of-pocket cost, not the WAC, determines real-world value for the patient. Manufacturer savings cards, Medicare Part D coverage tiers, and employer-plan formulary placement create enormous variation in what patients actually pay. A drug that is cost-effective at $200/month may be unaffordable and therefore valueless at $800/month.

The Broader Takeaway for GLP-1 Economics

LEADER established that a GLP-1 receptor agonist could reduce cardiovascular events in high-risk type 2 diabetes. The cost-effectiveness analyses that followed showed that clinical efficacy alone does not determine value. Price, patient selection, time horizon, and the opacity of US drug pricing all shape whether a given therapy meets economic thresholds. The lesson from LEADER's economic modeling is not that liraglutide was or was not "worth it," but that the answer depends entirely on which price you use, which patient you treat, and which health system is paying.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Marso SP, Daniels GH, Poulter NR, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. PubMed
  2. Kamble S, Engel SS, Engel-Nitz NM, et al. Cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes: LEADER versus ELIXA trial-based analysis. J Med Econ. 2018;21(7):657-665. PubMed
  3. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the ADA and EASD. Diabetes Care. 2018;41(12):2669-2701. PubMed
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
  5. Victoza (liraglutide) prescribing information. Novo Nordisk. FDA
  6. Hunt B, Malkin SJP, Moes RGJ, et al. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care. 2019;7(1):e000705. PubMed